Drug intelligence / Profile preview

HLK-0002

Development stage: Preclinical
Lead developer: HLK Pharmacin
Modality: Small Molecules

Overview

HLK-0002 is an investigational drug candidate being developed by Shenzhen Pharmacin for the treatment of androgen-related indications. The drug is currently in the formulation stage of development. Shenzhen Pharmacin specializes in the 505(b)(2) regulatory pathway, utilizing proprietary delivery technologies such as SpraySol™ to improve the solubility and bioavailability of existing active pharmaceutical ingredients. While the specific active ingredient for HLK-0002 has not been publicly disclosed in the provided English pipeline, the program is part of a portfolio targeting therapeutic areas including oncology, immunology, and dermatology.

Beyond the preview

Go deeper on HLK-0002.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on HLK-0002.

Explore the full profile